Enhancing asthma research and improving health equity through decentralized clinical trials (DCTs) and mHealth technology

Abstract

The COVID-19 pandemic led to widespread disruption and termination of clinical research and a prompt adoption of mobile health (mHealth) technologies in the healthcare space. As the United States’ healthcare system has rapidly become reliant on remotely conducted activities, the implementation of decentralized methods using mHealth technology in research investigation has become a necessary alternative to traditional in-person cohort studies. The aim of this article is to: report successful and unsuccessful examples of remote asthma clinical studies, explore the benefits and potential drawbacks of virtual clinical investigation, discuss the potential impact on equity and representation in asthma research, and provide suggestions through which investigators can implement decentralized clinical trials. Enhanced study accessibility, participant diversity, safety measures, and research efficacy are some of the benefits identified with a focused discussion on the impact on equity that decentralized clinical trials renders. Furthermore, potential concerns regarding regulatory compliance, data privacy, and effective mHealth design and solutions are discussed. Despite the setbacks and interruptions faced by the study participants and investigators due to the pandemic, the transition to decentralized clinical studies using mHealth technology is a positive, feasible step toward innovation and equity in the allergy and immunology field.

Keywords:

• Mobile health
• participant representation
• remote studies
• participant diversity
• virtual investigation

Disclosure statement

Dr. Jariwala has received grant support from the NIH, AHRQ, Stony Wold-Herbert Fund, PCORI, American Lung Association, Price Family Fund, Genentech, AstraZeneca, Sonde Health, and Einstein CTSA/National Center for Advancing Translational Sciences; and has served as a consultant and/or member of a scientific advisory board for Teva and Sanofi.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.